Software Patent Eligibility and the Learnings from the Japanese Experience in Addressing Challenges and Issues on Software Patenting
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Is Software Still Patentable?
Is Software Still Patentable? The last four years have posed significant hurdles to software patents; nevertheless they continue to be filed and allowed. By James J. DeCarlo and George Zalepa | August 20, 2018 | The Recorder Over the past four years, decisions by the Supreme Court and Federal Circuit, as interpreted by the U.S. Patent and Trademark Office, have had a dramatic effect on software-related inventions. These decisions have focused primarily on what comprises patentable subject matter under 35 U.S.C. § 101 and whether a patent’s specification adequately supports the claims. While uncertainty still exists, recent court decisions, coupled with sound prosecution strategies, can be used to bolster a practitioner’s arguments before the USPTO and courts. In Alice v. CLS Bank (2014), the Supreme Court applied the now familiar “two-part test” first laid out in Mayo v. Prometheus (2012). Under this test, a claim is first analyzed to determine if it is “directed to” an abstract idea. If so, the claim is then analyzed to determine whether it recites “significantly more” than the identified abstract idea or just “routine and conventional” elements. This test was (and is) routinely applied to software claims, and the pendulum of patentability for software inventions post-Alice swung firmly towards ineligibility. Nearly all decisions by the Federal Circuit in the immediate aftermath of Alice found claims ineligible. Similarly, the USPTO’s allowance rate in software-related art units plummeted, and many allowed but not yet issued applications were withdrawn by the USPTO. While many cases are representative of this period, the decision in Electric Power Group v. -
Japan Patent Office Long-Term Fellowship Program on The
Japan Patent Office Long-term Fellowship Program on the Intellectual Property under the Japan Patent Office FY2019 Research Theme: Considerations towards the adoption of the Patent Cooperation Treaty (PCT) in Argentina - Learning from the awareness and promo- tion of the PCT in Japan Submitted By Alejandro Javier Cafiero (Argentina) Universidad Nacional de La Plata (UNLP) Supervisor: Dr. Yorimasa Suwa Senior Researcher, APIC-JIPII Advisor: Prof. Junji Nakagawa Faculty of Liberal Arts, Chuo Gakuin University Mr. Daisuke NAGANO General Manager/ Patent Attorney Policy & Strategic, International Affairs Division Japan Intellectual Property Association The views and findings in this report are those of the author and do not necessarily reflect the views and policy of the organization or sponsor of this study. ○c JPO 2020 Abstract The Patent Cooperation Treaty (PCT) is a multilateral treaty of vital importance for the harmonization of the Patent system at the international level. Applicants of coun- tries that have accessed the PCT benefit by having affordable, simpler international filing procedures and speedier preliminary examinations. National Patent Offices are also im- proved by accessing the Treaty, as they are required to comply with several international standards. 153 countries have accessed the Treaty to date. Despite the advantages of taking part of the PCT, Argentina has refused to access it, mostly due to a lack of a national IP strategy, misconceptions about the PCT and the op-position of some domestic pharmaceutical companies. The lack of PCT availability in Argentinian puts domestic applicants at a disad- vantage against international counterparts. Such applicants range from universities, re- search centers and innovative companies to entrepreneurs and inventors. -
Patent Law: a Handbook for Congress
Patent Law: A Handbook for Congress September 16, 2020 Congressional Research Service https://crsreports.congress.gov R46525 SUMMARY R46525 Patent Law: A Handbook for Congress September 16, 2020 A patent gives its owner the exclusive right to make, use, import, sell, or offer for sale the invention covered by the patent. The patent system has long been viewed as important to Kevin T. Richards encouraging American innovation by providing an incentive for inventors to create. Without a Legislative Attorney patent system, the reasoning goes, there would be little incentive for invention because anyone could freely copy the inventor’s innovation. Congressional action in recent years has underscored the importance of the patent system, including a major revision to the patent laws in 2011 in the form of the Leahy-Smith America Invents Act. Congress has also demonstrated an interest in patents and pharmaceutical pricing; the types of inventions that may be patented (also referred to as “patentable subject matter”); and the potential impact of patents on a vaccine for COVID-19. As patent law continues to be an area of congressional interest, this report provides background and descriptions of several key patent law doctrines. The report first describes the various parts of a patent, including the specification (which describes the invention) and the claims (which set out the legal boundaries of the patent owner’s exclusive rights). Next, the report provides detail on the basic doctrines governing patentability, enforcement, and patent validity. For patentability, the report details the various requirements that must be met before a patent is allowed to issue. -
Patent and Trademark Cases Stephen Mcjohn
Northwestern Journal of Technology and Intellectual Property Volume 9 Article 1 Issue 4 January Spring 2011 Top Tens in 2010: Patent and Trademark Cases Stephen McJohn Recommended Citation Stephen McJohn, Top Tens in 2010: Patent and Trademark Cases, 9 Nw. J. Tech. & Intell. Prop. 1 (2011). https://scholarlycommons.law.northwestern.edu/njtip/vol9/iss4/1 This Perspective is brought to you for free and open access by Northwestern Pritzker School of Law Scholarly Commons. It has been accepted for inclusion in Northwestern Journal of Technology and Intellectual Property by an authorized editor of Northwestern Pritzker School of Law Scholarly Commons. NORTHWESTERN JOURNAL OF TECHNOLOGY AND INTELLECTUAL PROPERTY Top Tens in 2010: Patent and Trademark Cases Stephen McJohn January 2011 VOL. 9, NO. 4 © 2011 by Northwestern University School of Law Northwestern Journal of Technology and Intellectual Property Copyright 2011 by Northwestern University School of Law Volume 9, Number 4 (January 2011) Northwestern Journal of Technology and Intellectual Property Top Tens in 2010: Patent and Trademark Cases By Stephen McJohn* ¶1 The following are notable intellectual property decisions for patent and trademark in 2010 in the United States. Notable copyright and trade secret cases will be examined in a subsequent article. Viewed across doctrinal lines, some interesting threads emerge involving the scope of protection, the amount of secondary liability, and ownership of the intellectual property rights. ¶2 The scope of protection was at issue in both areas. Bilski v. Kappos marked a shift from using technical tests for patent subject matter to relying on the basic exclusions against patents on laws of nature, physical phenomena, or abstract ideas.1 Ass’n for Molecular Pathology v. -
"Reasonably" Compensate Employee Invento Rs in Japan
By Calvin GRIFFITH, MICHIRU Takahashi & Nobutaka KOMIyAMA bly" Compe ona nsat as e E "Re m o pl t o g ye n e i il In a v F e f n o t o s r l s l i a n f J t i a P p a e N h : T EMPLOYERS BEWARE The United States is generally considered a more litigious paying seven-figure sums in compensation for employee country than Japan, where customs traditionally favor a less inventions, having expected that the compensation provided confrontational approach to dispute resolution. But there is in the ordinary employment contract or internal employment one exception—employee invention lawsuits. A recent series regulations would be accepted by courts as reasonable. of lawsuits filed by aggrieved employee inventors against This stunning development in Japanese courts is based on their employer companies, demanding “reasonable remu- Japan’s unique employee invention system under Article neration” for the employees’ inventions, has brought atten- 35 of the Japan Patent Law, and foreign companies doing tion to this unique area of Japanese patent law—and raised business in Japan, especially those with R&D facilities there, concern in the business community. Japanese companies should be familiar with the provisions of Article 35 and the were shocked to find themselves facing the possibility of case law applying it. 14 orIgIn oF thE FUss—ArtIclE 35 AnD thE olyMPUs CasE be entitled to remuneration based on income from the pat- Article 35 of the Japan Patent law. Japan has a unique ents. Pursuant to those regulations, Olympus acquired a pat- employee invention system under Article 35 of the Patent ent on employee Tanaka’s invention. -
The Benefits of Japanese Patent Law System Over Those of the US in the Pharmaceutical Area
The Benefits of Japanese Patent Law System Over those of the US in the Pharmaceutical Area What can we do to maximize the benefits? William Han (GlaxoSmithKline) Japan Patent Attorneys Association International Activities Center 1 “Long Long Time Ago” • Poor Prosecution • Slow, Claim scope narrow if granted at all, claim types not sufficient • Weak Enforcement • Court proceedings took forever; Infringement/damages hard to prove; Damages minimal Regarding Enforcement: October 1994 – US Commissioner of Patents Bruce Lehman: “…the relative nonlitigiousness of Japanese society tends to minimize the importance of enforcement...US citizens holding Japanese patents should be able to rely on those patents more than their US patents…” Circa late 1990’s, JPO Commissioner Tekashi Isayama admitted: “The Japanese market is dishonorably regarded as ‘lenient towards infringement’. It is sometimes said that one may as well infringe whatever patents he likes in Japan, because court proceedings are slow and compensation insignificant” (taken from Mr Shusaku Yamamoto’s post) 2 • Aging population and attendant increase in healthcare cost, Japanese government started to aggressively promote the use of generic drug since 2007 • More numbers: • Sept 2016 – about 60% (by volume) • Japanese government wants to increase the use to 80% in fiscal year 2018-2020! • Patents are the only effective tools available to prevent the entry of generics 3 • Unlike in prior to 2007, opportunity cost of “not getting things right” in Japan could be enormous Comparison Between US v Japanese Patent Term Extension System • Both in Japan and US, if a drug undergoes clinical trial and review period, the patent which covers the drug can be extended up to 5 years. -
Best Mode Disclosure for Patent Applications: an International and Comparative Perspective
Journal of Intellectual Property Rights Vol 16, September 2011, pp 409-417 Best Mode Disclosure for Patent Applications: An International and Comparative Perspective Bingbin Lu† Nanjing University Law School, No 22, Hankou Road, Nanjing, 210 093, China Received 13 June 2011, revised 13 July 2011 The best mode disclosure requirement helps to ensure that the public receives a full and honest disclosure in return for the grant of patent. It has a profound theoretical basis and foundation. The best mode disclosure requirement is an optional obligation under the TRIPS Agreement in its Article 29. Among the most important developed countries that have implemented this disclosure requirement are the US and Japan; however, there are certain differences in their national laws and practices, especially with regard to the legal effect of this requirement. In the US, patent reform is tending towards removing the best mode disclosure from the list of reasons to invalidate a granted patent; although, the requirement will still apply to all patent applications during patent prosecutions. Developing countries are recommended to consider adopting the best mode disclosure requirement in their patent laws. It is proposed that patent applicants be required to disclose the best mode which shall be a substantive condition for patent grant; however, the failure to disclose the best mode may not constitute a reason to invalidate a granted patent. The objective of this article is to study the best mode disclosure requirement from an international and comparative perspective, and suggest how developing countries should implement this disclosure requirement. The article also seeks to answer to two questions: whether a developing country should implement the best mode disclosure requirement, and if so, how to best implement it? Keywords: Patent, best mode, disclosure requirements, TRIPS Agreement Disclosure is one of the key issues in the patent requirement is the first paragraph of Section 112, Title system. -
Does Strict Territoriality Toll the End of Software Patents?
NOTES DOES STRICT TERRITORIALITY TOLL THE END OF SOFTWARE PATENTS? James Ernstmeyer* INTRODUCTION ............................................................................................. 1267 I. UNITED STATES PROTECTION FOR INTELLECTUAL PROPERTY RIGHTS IN SOFTWARE ........................................................................ 1269 A. Defining Software ...................................................................... 1269 B. Copyright Protection for Software ............................................ 1270 C. Patent Protection for Software .................................................. 1272 D. The Backlash Against Intellectual Property Rights in Software ..................................................................................... 1274 E. In re Bilski Turns Back the Clock .............................................. 1278 II. UNITED STATES SOFTWARE PATENTS IN CROSS-BORDER TRADE .... 1280 A. Global Economic Stakes in United States Software Patents ..... 1280 B. Congressional Protection of Patents in Cross-Border Trade ......................................................................................... 1281 C. Extraterritoriality Concerns in Applying § 271(f) to Software Patents ........................................................................ 1283 III. DO PATENTS PROTECT SOFTWARE? – WOULD COPYRIGHTS DO BETTER? ............................................................................................ 1287 A. Effects of the Microsoft v. AT&T Loophole .............................. 1287 B. Combining -
U.S. Department of Commerce U.S. Patent and Trademark Office
Template Version Number: 01-2020 U.S. Department of Commerce U.S. Patent and Trademark Office Privacy Threshold Analysis for the Patent End to End (PE2E) System Template Version Number: 01-2020 U.S. Department of Commerce Privacy Threshold Analysis USPTO Patent End to End (PE2E) System Unique Project Identifier: PTOP-003-00 Introduction: This Privacy Threshold Analysis (PTA) is a questionnaire to assist with determining if a Privacy Impact Assessment (PIA) is necessary for this IT system. This PTA is primarily based from the Office of Management and Budget (OMB) privacy guidance and the Department of Commerce (DOC) IT security/privacy policy. If questions arise or further guidance is needed in order to complete this PTA, please contact your Bureau Chief Privacy Officer (BCPO). Description of the information system and its purpose: Provide a general description (in a way that a non-technical person can understand) of the information system that addresses the following elements: The E-Government Act of 2002 defines “ information system” by reference to the definition section of Title 44 of the United States Code. The following is a summary of the definition: “ Information system” means a discrete set of information resources organized for the collection, processing, maintenance, use, sharing, dissemination, or disposition of information. See: 44. U.S.C. § 3502(8). Patents End-to-End (PE2E) is a Master system portfolio consisting of next generation Patents Automated Information Systems (AIS). The goal of PE2E is to make the interaction of USPTO’s users as simple and efficient as possible in order to accomplish user goals. -
Finnegan Japan RT 07
JAPAN ROUNDTABLE: Avoid invalidity risks in court IN ASSOCIATION WITH: 2007 JAPAN: ROUNDTABLE Many companies fear that initiating a patent infringement lawsuit in Japan is tantamount to inviting the courts to invalidate their rights. MIP and Finnegan Henderson jointly hosted a roundtable in Tokyo to consider inventive step, invalidity and successful litigation techniques in one of the world’s most important markets Avoid invalidity risks In association with: in court PO: What are the factors that make it difficult for plaintiffs to win still not brought to the court – that only happens at stage three. Of patent litigation in Japan? course, the defendant would want to avoid the risk of an injunc- NY: There are a lot of good reasons to file patent litigation in tion and therefore they will try their best to reach some kind of res- Japan. It is very, very fast, and injunctions are available. You could olution, so only those cases where such resolutions were not pos- even say it is easier than in the US. Also, judges are very experi- sible would be taken to court. enced. But the major concern that many companies have is that in AI: The viewpoint of Mitsubishi Heavy Industries on patents more than 80% of cases – of course you can dispute the statistics and, I suppose, of Japanese companies in general is that of course – but in more than 80% of cases the patentee loses, and I think if your technical development has a positive outcome you would when you have such a low success rate you will think twice before want to protect it. -
There Is No Such Thing As a Software Patent
There is no such thing as a software patent 1 Kim Rubin BSEE/CS 45 years technology experience 4 startups 100+ inventions Patent Agent Author Taught computer security Book shelf for patents 2 {picture of file cabinets here} 3 There is no such thing as a software patent 4 7.5 5 7.4 6 7.3 7 There is no such thing as a software patent. There is no such thing as a rubber patent. There is no such thing as a steel patent. There is no such thing as an electricity patent. 8 There is only ... a patent. 9 pro se en banc said embodiment 10 Czapinski v. St. Francis Hosp., Inc., 2000 WI 80, ¶ 19, 236 Wis. 2d 316, 613 N.W.2d 120. v. The Federal Food, Drug, and Cosmetic Act (FDCA), ch. 675, 52 Stat. 1040, as amended, 21 U.S.C. § 301 et seq., iSee 21 U.S.C. § 355(a); Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661, 665—666, 674 (1990). 11 Article I, Section 8 8. “To promote the Progress of Science and useful Arts, by securing for limited Times to Inventors the exclusive Right to their Discoveries.” 12 Article I, Section 8 8. “To promote the Progress of Science and useful Arts, by securing for limited Times to Inventors the exclusive Right to their Discoveries … except for software.” 13 Jefferson, Congress, SCOTUS and MPEP 3. “The Act embodied Jefferson’s philosophy that ‘ingenuity should receive a liberal encouragement.’ 5 Writings of Thomas Jefferson, 75-76 Washington ed. 1871). -
Do Fixed Patent Terms Distort Innovation? Evidence from Cancer Clinical Trials
NBER WORKING PAPER SERIES DO FIXED PATENT TERMS DISTORT INNOVATION? EVIDENCE FROM CANCER CLINICAL TRIALS Eric Budish Benjamin N. Roin Heidi Williams Working Paper 19430 http://www.nber.org/papers/w19430 NATIONAL BUREAU OF ECONOMIC RESEARCH 1050 Massachusetts Avenue Cambridge, MA 02138 September 2013 Financial support from NIA Grant Number T32-AG000186 to the NBER, NSF Grant Number 1151497, the Chicago Booth Initiative on Global Markets, the NBER Innovation Policy and the Economy program, and the Petrie-Flom Center at Harvard Law School is gratefully acknowledged. We thank Meru Bhanot, David Burk, Toby Chaiken, Brian Cordonnier, Greg Howard, Niels Joaquin, Megan McGrath, and Ana Medrano-Fernandez for excellent research assistance. Daron Acemoglu, David Autor, Raj Chetty, Joe Doyle, Dan Fetter, Amy Finkelstein, Ray Fisman, Alberto Galasso, Amanda Kowalski, Anup Malani, Matt Notowidigdo, Felix Oberholzer-Gee, Ariel Pakes, Al Roth, Jon Skinner, Alan Sorensen, Scott Stern, Glen Weyl, and seminar participants at BEA, Carnegie Mellon, the CBO, the Cornell Empirical Patent Law Conference, Georgia Tech, Harvard Law School, MIT, the NBER (Industrial Organization, Law and Economics, Productivity, and Public Economics), the Northwestern Kellogg Healthcare Markets conference, Toulouse, UC-Berkeley Haas, UIUC, UVA, Wellesley, and Yale Law School provided very helpful comments. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research. NBER working papers are circulated for discussion and comment purposes. They have not been peer- reviewed or been subject to the review by the NBER Board of Directors that accompanies official NBER publications. © 2013 by Eric Budish, Benjamin N.